November 25, 2015
The FDA recently approved the first adjuvanted vaccine to prevent seasonal influenza in adults aged 65 years and older, according to a press release.
Fluad (Novartis Vaccines and Diagnostics) is a trivalent vaccine produced from two subtype A and one type B influenza virus strains. It is formulated with the adjuvant MF59, a squalene-based, oil-in-water emulsion. According to the CDC, adults aged 65 years and older account for 80% to 90% of seasonal influenza-related deaths and 50% to 70% of seasonal influenza-related hospitalizations.